Meeting
2022 ASCO Annual Meeting
Phase I clinical trial to assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of NY-ESO-1–specific TCR T-cells (TAEST16001) in HLA-A*02:01 patients with advanced soft tissue sarcoma.
Presenter
Xing Zhang
Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT04318964
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 11502)
DOI
10.1200/JCO.2022.40.16_suppl.11502
Abstract #
11502
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Pre-clinical modeling of navtemadlin pharmacokinetics (PK), pharmacodynamics (PD), and efficacy in glioblastoma, IDH-wildtype.
Speaker: Rachael A Vaubel, PhD
Speaker: Panel Discussion
Videos & Slides
2023 ASCO Annual Meeting
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRASG12C inhibitor, in advanced solid tumors.
Speaker: Yan Zhang
Speaker: Panel Discussion